GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (TSE:4569) » Definitions » EV-to-FCF

Kyorin Pharmaceutical Co (TSE:4569) EV-to-FCF : (As of May. 04, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Kyorin Pharmaceutical Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Kyorin Pharmaceutical Co's Enterprise Value is 円107,018 Mil. Kyorin Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was 円0 Mil. Therefore, Kyorin Pharmaceutical Co's EV-to-FCF for today is .

The historical rank and industry rank for Kyorin Pharmaceutical Co's EV-to-FCF or its related term are showing as below:

TSE:4569' s EV-to-FCF Range Over the Past 10 Years
Min: -14.51   Med: 14.48   Max: 28.23
Current: -14.38

During the past 13 years, the highest EV-to-FCF of Kyorin Pharmaceutical Co was 28.23. The lowest was -14.51. And the median was 14.48.

TSE:4569's EV-to-FCF is ranked worse than
100% of 509 companies
in the Drug Manufacturers industry
Industry Median: 22.78 vs TSE:4569: -14.38

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-04), Kyorin Pharmaceutical Co's stock price is 円1839.00. Kyorin Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was 円74.268. Therefore, Kyorin Pharmaceutical Co's PE Ratio for today is 24.76.


Kyorin Pharmaceutical Co EV-to-FCF Historical Data

The historical data trend for Kyorin Pharmaceutical Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyorin Pharmaceutical Co EV-to-FCF Chart

Kyorin Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -28.62 25.78 1,561.82 26.25 -13.46

Kyorin Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -13.46 - - -

Competitive Comparison of Kyorin Pharmaceutical Co's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyorin Pharmaceutical Co's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's EV-to-FCF falls into.



Kyorin Pharmaceutical Co EV-to-FCF Calculation

Kyorin Pharmaceutical Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=107017.938/0
=

Kyorin Pharmaceutical Co's current Enterprise Value is 円107,018 Mil.
Kyorin Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kyorin Pharmaceutical Co  (TSE:4569) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Kyorin Pharmaceutical Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1839.00/74.268
=24.76

Kyorin Pharmaceutical Co's share price for today is 円1839.00.
Kyorin Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円74.268.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Kyorin Pharmaceutical Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Kyorin Pharmaceutical Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyorin Pharmaceutical Co (TSE:4569) Business Description

Traded in Other Exchanges
N/A
Address
6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co (TSE:4569) Headlines

No Headlines